CClinicalTrials.gg
Active, not recruitingNCT05585866PROSACCUpdated May 8, 2024

Propofol and Sevoflurane Anesthesia in Colorectal Cancer Surgery: Incidence of Acute Kidney Injury

An observational study in Acute Kidney Injury and Cancer Colorectal, sponsored by Uppsala University. Active, not recruiting at 1 site in Sweden. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by Uppsala University · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
4,000
Sex
All
01

Study summary

The goal of this observational study is to compare anesthetic modalities (intravenous propofol anesthesia with sevoflurane gas anesthesia) in patients who underwent colorectal cancer resection surgery regarding the outcome of acute kidney injury.

The main questions it aims to answer are:

  • is there a difference in acute kidney injury incidence in the two anesthetic modalities?
  • is there a difference in plasma creatinine between the two anesthetic modalities?
  • are there any patient characteristics or intraoperative factors that effect the incidence of acute kidney injury in either anesthetic modality?

The study will analyze data from the CAN clinical trial database. (Cancer and Anesthesia: Survival After Radical Surgery - a Comparison Between Propofol or Sevoflurane Anesthesia, NCT01975064)

02

Conditions studied

  • Acute Kidney Injury
  • Cancer Colorectal

Keywords

  • sevoflurane
  • propofol
  • plasma creatinine
03

In context

Acute Kidney Injury

1,595 studies on the registry are indexed under Acute Kidney Injury; 371 are open to participants now.

This study's planned enrollment of 4,000 is above the median of 150 across 773 observational studies indexed under Acute Kidney Injury.

Browse Acute Kidney Injury studies →

Lead sponsor

Uppsala University is the lead sponsor of 381 studies on the registry; 84 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who underwent colorectal cancer resection surgery and gave consent to participate in the CAN trial.

Inclusion criteria

  • colorectal surgery and participant in the CAN trial

Exclusion criteria

Exclusion Criteria:

  • missing blood samples
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
4,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Sevoflurane

    The group of patients which received sevoflurane as randomized anesthetic modality.

    Drug: Anesthesia Agent

  • Propofol

    The group of patients which received propofol as randomized anesthetic modality.

    Drug: Anesthesia Agent

Interventions

  • DrugAnesthesia Agent

    The two anesthetic modalities included intravenous propofol anesthesia and sevoflurane gas anesthesia administered according to standard clinical praxis.

06

What researchers measure

Primary outcomes

  1. Acute Kidney Injury

    Compare the incidence of AKI (n, %) in the two anesthetic modalities. Number of participants (n, %) with AKI and number of participants (n, %) with AKI stage 1-3 within the different anesthetic modalities at 0-3 days and 4-10 days postoperatively. KDIGO (Kidney Disease: Improving Global Outcome) criteria for plasma creatinine are used as criteria for AKI. The highest value of plasma creatinine within the time frame will be used to define AKI stage.

    Time frame: Within 10 days of surgery

  2. Changes in plasma creatinine

    Changes in plasma creatinine over time in both groups of anesthesia. Plasma creatinine from preoperative, postoperative after 0-3 days, postoperative 4-10 days and after 30 days. Maximum plasma creatinine for each participant at these time point will be used in the regression analysis.

    Time frame: Within 30 days of surgery

Secondary outcomes

  1. AKI incidence in the cardiovascular disease population

    Compare the incidence of AKI (n, %) during the two anesthetic modalities in the population with present cardiovascular disease. Classified according to KDIGO AKI stage 1-3 changes in plasma creatinine. The highest value of plasma creatinine within the time frame will be used to define AKI stage.

    Time frame: Within 10 days of surgery

  2. Association of sex on AKI incidence

    Compare the incidence of AKI (n, %) in men vs women. This analysis will be done in both groups separately and in the entire population independent of anesthetic modality.

    Time frame: Within 10 days of surgery

  3. Association of age on AKI incidence

    Compare the incidence of AKI (n, %) in participants older vs younger than 65. This analysis will be done in both groups separately and in the entire population independent of anesthetic modality.

    Time frame: Within 10 days of surgery

07

Study locations

1 site
  • Uppsala University
    Uppsala, 75185, Sweden
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05585866
Lead sponsor
Uppsala University
Responsible party
Sponsor
First posted
Oct 19, 2022
Start date
Nov 22, 2021
Primary completion
Oct 31, 2022
Completion
Dec 31, 2025 (estimated)
Last update
May 8, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion